<DOC>
	<DOCNO>NCT00648960</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Genpharm 's clarithromycin tablet follow single , oral 500 mg ( 1 x 500 mg ) dose compare Biaxin速 filmtab速 ( Abbott Laboratories USA ) administer fasting condition . Sixty-four ( 64 ) healthy , light- , non- ex-smoking subject least 18 year age randomize , two-period , two-treatment crossover bioequivalence study conduct Eric Sicard , M.D . Algorithme Pharma Inc. Montreal , Canada . Statistical analysis data reveals 90 % confidence interval within acceptable bioequivalent range 80 % 125 % natural log transform parameter AUCT , AUCI Cmax . This study demonstrate Genpharm 's clarithromycin 500 mg tablet bioequivalent Biaxin速 filmtab速 500 mg tablet ( Abbott Laboratories USA ) administer fasting condition .</brief_summary>
	<brief_title>Comparative Bioavailability Study Clarithromycin 500 mg Tablets Fasting State</brief_title>
	<detailed_description />
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Subjects meet follow criterion may include study : Availability subject entire study period willingness adhere protocol requirement evidence informed consent form duly sign subject Males female age 18 55 year body mass index ( BMI ) great equal 19 30 ; demographic data ( sex , age , ethnic group , body weight , height smoke habit ) record report final report Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance must record CRF ( laboratory test present section 7.1.3 ) Healthy accord laboratory result physical examination Significant history hypersensitivity clarithromycin , erythromycin , macrolide antibacterial agent related product well severe hypersensitivity reaction ( like angioedema ) drug Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease Females pregnant , lactate likely become pregnant study phase Females childbearing potential refuse use acceptable contraceptive regimen throughout study Positive pregnancy test study Use follow product ( astemizole , terfenadine , cisapride pimozide ) previous 14 day day 1 study Maintenance therapy drug , significant history drug dependency , alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) , serious psychological disease Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug previous 28 day day 1 study ( barbiturate , corticosteroid , phenylhydantoins , etc . ) Participation another clinical trial previous 28 day day 1 study Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study Positive urine screen drug abuse ( drug names present section 7.1.4 ) Positive result HIV , HBsAg antiHCV test History faint upon blood sampling</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>